Vir Biotechnology (VIR)
(Real Time Quote from BATS)
$10.12 USD
+0.02 (0.20%)
Updated Mar 28, 2024 03:48 PM ET
After-Market: $10.12 0.00 (0.00%) 4:06 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
VIR 10.12 +0.02(0.20%)
Will VIR be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VIR
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why
Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?
Other News for VIR
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)
Commit To Purchase Vir Biotechnology At $7.50, Earn 8.9% Annualized Using Options
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio